Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result.

ABSTRACT:

Introduction

CAR-T cell therapy has revolutionized the therapeutic landscape for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), and bridging with allogeneic hematopoietic stem cell transplantation (allo-HSCT) has the potential to lower relapse rates. Nevertheless, the majority of existing studies have exclusively focused on short-term outcomes, resulting in a lack of comprehensive understanding of the long-term sustainability of overall prognosis.

Objectives

Our study aimed to provide real-world, long-term follow-up data for patients who underwent sequential therapy.

Methods

Patients with R/R B-ALL who achieved MRD^-CR following CAR-T therapy and subsequently underwent allo-HSCT between January 2016 and May 2024 were enrolled. The pri

SUBMITTER: Yang T 

PROVIDER: S-EPMC12684954 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature